Top

Published in:

01-09-2012 | Decompensated Heart Failure (MM Givertz, Section editor)

Mid-Regional Pro-Adrenomedullin in Acute Heart Failure: A Better Biomarker or Just Another Biomarker?

Authors: Mihael Potocki, Ronny Ziller, Christian Mueller

Published in: Current Heart Failure Reports | Issue 3/2012

Abstract

Circulating biomarkers have become increasingly important in diagnosing and risk-stratifying patients with heart failure (HF). While the natriuretic peptides have received much focus in the past decade, there is increasing interest in the role of other circulating biomarkers such as mid-regional proadrenomedullin (MR-proADM), a stable peptide of the precursor of adrenomedullin (ADM), responsible for volume regulation and electrolyte homeostasis. Increased levels of MR-proADM are associated with an increased risk of mortality and morbidity in patients with HF, independent of natriuretic peptides. MR-proADM outperforms all other established markers in the identification of patients at highest risk of death, particularly death within 30 days. The prognostic superiority has consistently been shown for various cardiovascular disease states, including acute heart failure. In this article, we discuss the potential role of MR-proADM in the syndrome of acute heart failure and its implication on prognosis and risk stratification.

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.

Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA. Rapid measurement of b-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–7.PubMedCrossRef

Januzzi Jr JL, Sakhuja R, O’Donoghue M, Baggish AL, Anwaruddin S, Chae CU, Cameron R, Krauser DG, Tung R, Camargo Jr CA, Lloyd-Jones DM. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006;166:315–20.PubMedCrossRef

Peacock WFt, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117–26.PubMedCrossRef

Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble st2 receptor as a novel heart failure biomarker. Circulation. 2003;107:721–6.PubMedCrossRef

Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007;115:949–52.PubMedCrossRef

Nakamura M, Yoshida H, Makita S, Arakawa N, Niinuma H, Hiramori K. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. Circulation. 1997;95:1214–21.PubMedCrossRef

Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993;192:553–60.PubMedCrossRef

Nicholls MG, Charles CJ, Lainchbury JG, Lewis LK, Rademaker MT, Richards AM, Yandle TG. Adrenomedullin in heart failure. Hypertens Res. 2003;26(Suppl):S135–40.PubMedCrossRef

10.

Kato J, Kobayashi K, Etoh T, Tanaka M, Kitamura K, Imamura T, Koiwaya Y, Kangawa K, Eto T. Plasma adrenomedullin concentration in patients with heart failure. J Clin Endocrinol Metab. 1996;81:180–3.PubMedCrossRef

11.

Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW. Plasma n-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 1998;97:1921–9.PubMedCrossRef

12.

Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000;21:138–67.PubMedCrossRef

13.

Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides. 2004;25:1369–72.PubMedCrossRef

14.

Khan SQ, O’Brien RJ, Struck J, Quinn P, Morgenthaler N, Squire I, Davies J, Bergmann A, Ng LL. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the lamp (leicester acute myocardial infarction peptide) study. J Am Coll Cardiol. 2007;49:1525–32.PubMedCrossRef

15.

Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Haltmayer M, Mueller T. Comparative evaluation of b-type natriuretic peptide, mid-regional pro-a-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail. 2007;13:42–9.PubMedCrossRef

16.

Behnes M, Papassotiriou J, Walter T, Fiedler E, Sauer T, Lang S, Elmas E, Hoffmann U, Borggrefe M, Brueckmann M. Long-term prognostic value of mid-regional pro-adrenomedullin and c-terminal pro-endothelin-1 in patients with acute myocardial infarction. Clin Chem Lab Med. 2008;46:204–11.PubMedCrossRef

17.

Adlbrecht C, Hulsmann M, Strunk G, Berger R, Mortl D, Struck J, Morgenthaler NG, Bergmann A, Jakowitsch J, Maurer G, Lang IM, Pacher R. Prognostic value of plasma midregional pro-adrenomedullin and c-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail. 2009;11:361–6.PubMedCrossRef

18.

Gombos T, Forhecz Z, Pozsonyi Z, Wallentin S, Papassotiriou J, Kunde J, Morgenthaler NG, Janoskuti L, Prohaszka Z. Adrenomedullin and endothelin-1 are related to inflammation in chronic heart failure. Inflamm Res. 2009;58:298–305.PubMedCrossRef

19.

Potocki M, Breidthardt T, Reichlin T, Morgenthaler NG, Bergmann A, Noveanu M, Schaub N, Uthoff H, Freidank H, Buser L, Bingisser R, Christ M, Mebazaa A, Mueller C. Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. Crit Care. 2009;13:R122.PubMedCrossRef

20.

Masson S, Latini R, Carbonieri E, Moretti L, Rossi MG, Ciricugno S, Milani V, Marchioli R, Struck J, Bergmann A, Maggioni AP, Tognoni G, Tavazzi L, Investigators G-H. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the gissi-heart failure (gissi-hf) trial. Eur J Heart Fail. 2010;12:338–47.PubMedCrossRef

21.

von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, Doehner W, Rozentryt P, Vassanelli C, Struck J, Banasiak W, Ponikowski P, Kremastinos D, Bergmann A, Morgenthaler NG, Anker SD. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail. 2010;12:484–91.CrossRef

22.

Klip IT, Voors AA, Anker SD, Hillege HL, Struck J, Squire I, van Veldhuisen DJ, Dickstein K, OPTIMAAL Investigators. Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction. Heart. 2011;97:892–8.

23.

•• Maisel A, Mueller C, Nowak RM, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng LL, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Hartmann O, Morgenthaler NG, Anker SD. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the bach (biomarkers in acute heart failure) trial. J Am Coll Cardiol. 2011;58:1057–67. This prospective, multicenter, international study included 1,641 patients presenting to the emergency department with dyspnea. In the subgroup of 568 patients diagnosed with acute heart failure, MR-proADM was superior to BNP and NT-proBNP for predicting 90-day mortality and especially 30-day mortality.PubMedCrossRef

24.

Peacock WF, Nowak R, Christenson R, DiSomma S, Neath SX, Hartmann O, Mueller C, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Filippatos GS, Anand I, Ng LL, Daniels LB, Morgenthaler N, Anker SD, Maisel AS. Short-term mortality risk in emergency department acute heart failure. Acad Emerg Med. 2011;18:947–58.PubMedCrossRef

25.

Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the bach (biomarkers in acute heart failure) trial. J Am Coll Cardiol. 2010;55:2062–76.PubMedCrossRef

26.

Shimosawa T, Fujita T. Adrenomedullin and its related peptide. Endocr J. 2005;52:1–10.PubMedCrossRef

27.

Kitamura K, Kangawa K, Ishiyama Y, Washimine H, Ichiki Y, Kawamoto M, Minamino N, Matsuo H, Eto T. Identification and hypotensive activity of proadrenomedullin n-terminal 20 peptide (pamp). FEBS Lett. 1994;351:35–7.PubMedCrossRef

28.

Watanabe TX, Itahara Y, Inui T, Yoshizawa-Kumagaye K, Nakajima K, Sakakibara S. Vasopressor activities of n-terminal fragments of adrenomedullin in anesthetized rat. Biochem Biophys Res Commun. 1996;219:59–63.PubMedCrossRef

29.

Gumusel B, Hao Q, Hyman AL, Kadowitz PJ, Champion HC, Chang JK, Mehta JL, Lippton H. Analysis of responses to adrenomedullin-(13–52) in the pulmonary vascular bed of rats. Am J Physiol. 1998;274:H1255–63.PubMed

30.

Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, Foord SM. International union of pharmacology. Xxxii. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002;54:233–46.PubMedCrossRef

31.

Lopez J, Martinez A. Cell and molecular biology of the multifunctional peptide, adrenomedullin. Int Rev Cytol. 2002;221:1–92.PubMedCrossRef

32.

Tomoda Y, Isumi Y, Katafuchi T, Minamino N. Regulation of adrenomedullin secretion from cultured cells. Peptides. 2001;22:1783–94.PubMedCrossRef

33.

Zhou M, Chaudry IH, Wang P. The small intestine is an important source of adrenomedullin release during polymicrobial sepsis. Am J Physiol Regul Integr Comp Physiol. 2001;281:R654–60.PubMed

34.

Zhou M, Chaudry IH, Wang P. Adrenomedullin is upregulated in the heart and aorta during the early and late stages of sepsis. Biochim Biophys Acta. 1999;1453:273–83.PubMedCrossRef

35.

Washimine H, Asada Y, Kitamura K, Ichiki Y, Hara S, Yamamoto Y, Kangawa K, Sumiyoshi A, Eto T. Immunohistochemical identification of adrenomedullin in human, rat, and porcine tissue. Histochem Cell Biol. 1995;103:251–4.PubMedCrossRef

36.

Ishimitsu T, Miyata A, Matsuoka H, Kangawa K. Transcriptional regulation of human adrenomedullin gene in vascular endothelial cells. Biochem Biophys Res Commun. 1998;243:463–70.PubMedCrossRef

37.

Sugo S, Minamino N, Kangawa K, Miyamoto K, Kitamura K, Sakata J, Eto T, Matsuo H. Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun. 1994;201:1160–6.PubMedCrossRef

38.

Meeran K, O’Shea D, Upton PD, Small CJ, Ghatei MA, Byfield PH, Bloom SR. Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab. 1997;82:95–100.PubMedCrossRef

39.

Lewis LK, Smith MW, Yandle TG, Richards AM, Nicholls MG. Adrenomedullin(1–52) measured in human plasma by radioimmunoassay: plasma concentration, adsorption, and storage. Clin Chem. 1998;44:571–7.PubMed

40.

Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem. 2005;51:1823–9.PubMedCrossRef

41.

Ishiyama Y, Kitamura K, Ichiki Y, Nakamura S, Kida O, Kangawa K, Eto T. Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats. Eur J Pharmacol. 1993;241:271–3.PubMedCrossRef

42.

Jougasaki M, Stevens TL, Borgeson DD, Luchner A, Redfield MM, Burnett Jr JC. Adrenomedullin in experimental congestive heart failure: cardiorenal activation. Am J Physiol. 1997;273:R1392–9.PubMed

43.

Lainchbury JG, Troughton RW, Lewis LK, Yandle TG, Richards AM, Nicholls MG. Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers. J Clin Endocrinol Metab. 2000;85:1016–20.PubMedCrossRef

44.

Tsuruda T, Kato J, Kitamura K, Kuwasako K, Imamura T, Koiwaya Y, Kangawa K, Eto T. Secretion of proadrenomedullin n-terminal 20 peptide from cultured neonatal rat cardiac cells. Life Sci. 2001;69:239–45.PubMedCrossRef

45.

Chun TH, Itoh H, Saito T, Yamahara K, Doi K, Mori Y, Ogawa Y, Yamashita J, Tanaka T, Inoue M, Masatsugu K, Sawada N, Fukunaga Y, Nakao K. Oxidative stress augments secretion of endothelium-derived relaxing peptides, c-type natriuretic peptide and adrenomedullin. J Hypertens. 2000;18:575–80.PubMedCrossRef

46.

Chun TH, Itoh H, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Doi K, Inoue M, Masatsugu K, Korenaga R, Ando J, Nakao K. Shear stress augments expression of c-type natriuretic peptide and adrenomedullin. Hypertension. 1997;29:1296–302.PubMedCrossRef

47.

Cormier-Regard S, Nguyen SV, Claycomb WC. Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. J Biol Chem. 1998;273:17787–92.PubMedCrossRef

48.

Nishikimi T, Yoshihara F, Mori Y, Kangawa K, Matsuoka H. Cardioprotective effect of adrenomedullin in heart failure. Hypertens Res. 2003;26(Suppl):S121–7.PubMedCrossRef

49.

Hirata Y, Hayakawa H, Suzuki Y, Suzuki E, Ikenouchi H, Kohmoto O, Kimura K, Kitamura K, Eto T, Kangawa K, et al. Mechanisms of adrenomedullin-induced vasodilation in the rat kidney. Hypertension. 1995;25:790–5.PubMedCrossRef

50.

Tsuruda T, Kato J, Kitamura K, Kuwasako K, Imamura T, Koiwaya Y, Tsuji T, Kangawa K, Eto T. Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. Hypertension. 1998;31:505–10.PubMedCrossRef

51.

Inatsu H, Sakata J, Shimokubo T, Kitani M, Nishizono M, Washimine H, Kitamura K, Kangawa K, Matsuo H, Eto T. Distribution and characterization of rat immunoreactive proadrenomedullin n-terminal 20 peptide (pamp) and the augmented cardiac pamp in spontaneously hypertensive rat. Biochem Mol Biol Int. 1996;38:365–72.PubMed

52.

Romppanen H, Marttila M, Magga J, Vuolteenaho O, Kinnunen P, Szokodi I, Ruskoaho H. Adrenomedullin gene expression in the rat heart is stimulated by acute pressure overload: blunted effect in experimental hypertension. Endocrinology. 1997;138:2636–9.PubMedCrossRef

53.

Nishikimi T, Horio T, Sasaki T, Yoshihara F, Takishita S, Miyata A, Matsuo H, Kangawa K. Cardiac production and secretion of adrenomedullin are increased in heart failure. Hypertension. 1997;30:1369–75.PubMedCrossRef

54.

Niu P, Shindo T, Iwata H, Iimuro S, Takeda N, Zhang Y, Ebihara A, Suematsu Y, Kangawa K, Hirata Y, Nagai R. Protective effects of endogenous adrenomedullin on cardiac hypertrophy, fibrosis, and renal damage. Circulation. 2004;109:1789–94.PubMedCrossRef

55.

Kawai J, Ando K, Tojo A, Shimosawa T, Takahashi K, Onozato ML, Yamasaki M, Ogita T, Nakaoka T, Fujita T. Endogenous adrenomedullin protects against vascular response to injury in mice. Circulation. 2004;109:1147–53.PubMedCrossRef

56.

Jougasaki M, Wei CM, McKinley LJ, Burnett Jr JC. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation. 1995;92:286–9.PubMedCrossRef

57.

Hamada M, Shigematsu Y, Kawakami H, Minamino N, Kangawa K, Matsuo H, Hiwada K. Increased plasma levels of adrenomedullin in patients with hypertrophic cardiomyopathy: its relation to endothelin-i, natriuretic peptides and noradrenaline. Clin Sci (Lond). 1998;94:21–8.

58.

Lainchbury JG, Cooper GJ, Coy DH, Jiang NY, Lewis LK, Yandle TG, Richards AM, Nicholls MG. Adrenomedullin: a hypotensive hormone in man. Clin Sci (Lond). 1997;92:467–72.

59.

Nagaya N, Satoh T, Nishikimi T, Uematsu M, Furuichi S, Sakamaki F, Oya H, Kyotani S, Nakanishi N, Goto Y, Masuda Y, Miyatake K, Kangawa K. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation. 2000;101:498–503.PubMedCrossRef

60.

Bhandari SS, Davies JE, Struck J, Ng LL. Influence of confounding factors on plasma mid-regional pro-adrenomedullin and mid-regional pro-a-type natriuretic peptide concentrations in healthy individuals. Biomarkers. 2011;16:281–7.PubMedCrossRef

61.

Li Y, Jiang C, Wang X, Zhang Y, Shibahara S, Takahashi K. Adrenomedullin is a novel adipokine: adrenomedullin in adipocytes and adipose tissues. Peptides. 2007;28:1129–43.PubMedCrossRef

62.

Shimosawa T, Ogihara T, Matsui H, Asano T, Ando K, Fujita T. Deficiency of adrenomedullin induces insulin resistance by increasing oxidative stress. Hypertension. 2003;41:1080–5.PubMedCrossRef

63.

Dieplinger B, Mueller T, Kollerits B, Struck J, Ritz E, von Eckardstein A, Haltmayer M, Kronenberg F, Group MS. Pro-a-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the mmkd study. Kidney Int. 2009;75:408–14.PubMedCrossRef

64.

Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton C, Turner J, Crozier IG, Yandle TG. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 2003;107:2786–92.PubMedCrossRef

65.

Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. N-terminal pro-b-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004;110:3206–12.PubMedCrossRef

66.

Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald E. Evaluation of b-type natriuretic peptide for risk assessment in unstable angina/non-st-elevation myocardial infarction: B-type natriuretic peptide and prognosis in tactics-timi 18. J Am Coll Cardiol. 2003;41:1264–72.PubMedCrossRef

67.

Wild PS, Schnabel RB, Lubos E, Zeller T, Sinning CR, Keller T, Tzikas S, Lackner KJ, Peetz D, Rupprecht HJ, Bickel C, Morgenthaler NG, Papassotiriou J, Tiret L, Munzel T, Blankenberg S. Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the atherogene study. Clin Chem. 2012;58:226–36.PubMedCrossRef

68.

Nishikimi T, Saito Y, Kitamura K, Ishimitsu T, Eto T, Kangawa K, Matsuo H, Omae T, Matsuoka H. Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol. 1995;26:1424–31.PubMedCrossRef

69.

Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, Espiner EA, Frampton C, Yandle TG. Plasma n-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-new zealand heart failure group. J Am Coll Cardiol. 2001;37:1781–7.PubMedCrossRef

70.

Pousset F, Masson F, Chavirovskaia O, Isnard R, Carayon A, Golmard JL, Lechat P, Thomas D, Komajda M. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur Heart J. 2000;21:1009–14.PubMedCrossRef

71.

Lee DS, Schull MJ, Alter DA, Austin PC, Laupacis A, Chong A, Tu JV, Stukel TA. Early deaths in patients with heart failure discharged from the emergency department: a population-based analysis. Circ Heart Fail. 2010;3:228–35.PubMedCrossRef

Title: Mid-Regional Pro-Adrenomedullin in Acute Heart Failure: A Better Biomarker or Just Another Biomarker?
Authors: Mihael Potocki
Ronny Ziller
Christian Mueller
Publication date: 01-09-2012
Publisher: Current Science Inc.
Published in: Current Heart Failure Reports / Issue 3/2012
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-012-0096-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Mid-Regional Pro-Adrenomedullin in Acute Heart Failure: A Better Biomarker or Just Another Biomarker?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

AMP-activated Protein Kinase in the Control of Cardiac Metabolism and Remodeling

Recoupling the Cardiac Nitric Oxide Synthases: Tetrahydrobiopterin Synthesis and Recycling

New Treatment Options for Late Na Current, Arrhythmias, and Diastolic Dysfunction

Cardiac Role of Cyclic-GMP Hydrolyzing Phosphodiesterase Type 5: From Experimental Models to Clinical Trials

Cardiac Side Effects of Anticancer Treatments: New Mechanistic Insights

Management of Acute Right Ventricular Failure in the Intensive Care Unit

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page